Slide 1: Investor Presentation Financial Year 2016/17
For personal use only Investor Presentation Financial Year 2016/17 Investor Presentation | Slide 0
Slide 2: Disclaimer & Regulatory Disclosure
Disclaimer & Regulatory Disclosure For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Global Highlights 2016/17 – A Transitional Year
Global Highlights 2016/17 – A Transitional Year For personal use only Renew Sleep Solutions (“RSS”) – Seven centres opened in 2016/17 • Head office organisation, reimbursement and claims capabilities fully established • Seven centres opened across six states in the US in the first year of trading an
Slide 4: Continuing growth and expansion
Continuing growth and expansion For personal use only Global unit sales growth Global revenue growth Units A$’000 60,000 80,000 68,100 $49.3m 70,000 50,000 $44.1m 58,983 60,000 51,355 40,000 $34.4m Other 50,000 43,438 $30.3m revenues Units +20.0% 30,000 40,000 +15.5% 30,000 20,000 MAS revenues 20,00
Slide 5: Improving margins
Improving margins For personal use only MAS Gross Margin % Group Gross Margin % % % 75 60 58.4% 70.0% 70 58 65 56 60 54 55 52 50 50 2013/14 2014/15 2015/16 2016/17 2013/14 2014/15 2015/16 2016/17 MAS Gross Margin Group Gross Margin Investor Presentation | Slide 4
Slide 6: Strong growth in SOM core business EBITDA
Strong growth in SOM core business EBITDA For personal use only EBITDA* A$’000 2,500 $2.366m 2,000 +60% 1,500 1,000 500 0 2013/14 2014/15 2015/16 2016/17 * EBITDA as adjusted does not include share and option expense, gain/(loss) on contingent consideration payable and impairment of goodwill Investo
Slide 7: Renew Sleep Solutions successfully launched
Renew Sleep Solutions successfully launched For personal use only • Strategic “Direct To Patient” channel opened 2016/17 with 7 new centres across 6 states within the US confirms ability to build network aggressively • Total investment of SOM in RSS in 2016/17 US$4.6m (A$6.2m) • Dallas based executi
Slide 8: SomnoMed core business
SomnoMed core business For personal use only North America – transitional year due to impact of RSS • Announcement of RSS launch impacted on sales in 2nd and 3rd quarter in NA. Q4 return to growth in US (+24%) indicates that perceived channel conflict is being successfully navigated. Total volume gr
Slide 9: Summary Profit & Loss
Summary Profit & Loss For personal use only Financial Summary – AUD $000’s SomnoMed SomnoMed SomnoMed SomnoMed Core Core RSS Core Group FY16/17 FY15/16 FY16/17 FY16/17 FY16/17 Revenue 47,740 44,084 8.3% 1,587 47,740 49,327 Gross margin 27,835 25,343 10.0% 9.8% 974 27,835 28,809 Sales and marketing e
Slide 10: Assumptions 2017/18
Assumptions 2017/18 For personal use only SomnoMed Core • Revenues to grow >15% to >A$55m • Operating profit before corporate, research and business development expenses, non-cash items and income tax, to grow 60% to A$10.5m Renew Sleep Solutions • 10-12 new centres to be opened in 2017/18 • Total r
Slide 11: Record year ahead for SomnoMed
Record year ahead for SomnoMed 2017/18 Guidance For personal use only • Transition to a sleep solutions based company will continue and expand in 2017/18 • Guidance: Revenues expected to grow by 60% from $50 million to between $75-$80 million EBITDA* to grow significantly in 2017/18 to $5 millio
Slide 12: Contact details
Contact details For personal use only CHIEF EXECUTIVE OFFICER Mr. Derek Smith CHIEF FINANCIAL OFFICER Mr. Neil Verdal-Austin Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (2) 9467 0400 Website www.somnomed.com.au Investor Presentation | Slide 11